Effectiveness and safety of tenofovir alafenamide in children and adolescents living with HIV: a systematic review.

ABSTRACT:

Introduction

Tenofovir alafenamide (TAF) is approved for paediatric use in fixed-dose combination tablets, but efficacy and safety data in children are limited. We conducted a systematic review on the efficacy/effectiveness and safety of TAF in infants, children and adolescents living with HIV.

Methods

We searched MEDLINE, Embase, the Cochrane Library, clinical trial registries, reference lists and relevant conferences to identify literature published January 2009-March 2021. We included clinical trials and observational studies assessing the efficacy/effectiveness or safety of TAF through ≥6 months of treatment in participants aged 0-19 years.

Results and discussion

Overall 3626 abstracts and 371 full papers were screened. Four single-arm, innovator-funded trials (34

SUBMITTER: O'Rourke J 

PROVIDER: S-EPMC9950035 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature